These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19667964)

  • 1. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
    Coto E; Tavira B
    Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
    Utecht KN; Hiles JJ; Kolesar J
    Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
    Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY; Teng RC; Zhu HJ; Fang Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
    Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.
    Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Alvarez V;
    Clin Chem Lab Med; 2011 May; 49(5):825-33. PubMed ID: 21480817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.
    Quteineh L; Verstuyft C
    Curr Opin Organ Transplant; 2010 Oct; 15(5):601-7. PubMed ID: 20720493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.